Research & Development

ATAI Life Sciences and Cyclica launch joint venture to revolutionise drug development for mental health disorders

ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, and Cyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the drug discovery process, have launched a joint venture aimed at changing the paradigm in which mental health disorders are treated.

Stone Capital Partners Biosyngen to setup $50m biopharmaceutical investment fund in Singapore

Stone Capital and Biosyngen have partnered to establish a Biopharmaceutical Investment Fund in Singapore, the signing ceremony was held in Ascendas One Hub of Sino-Singapore Guangzhou Knowledge City.

Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments

Regeneron Pharmaceuticals has entered into a research collaboration and option licencing agreement with Vyriad to discover and develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer.

Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design

Cyclica, Inc. today announced a collaboration with Enamine Ltd., the world’s largest chemical supplier, to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand Design platform.

A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics

A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients, announced its official launch.

Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance

Boehringer Ingelheim and Eli Lilly and Company will modernise their current alliance as of 1 January 2020 and focus its combined expertise and investment on the continued development and commercialisation of Jardiance (empagliflozin) in type 2 diabetes, heart failure, and chronic kidney disease.

Amgen enters into strategic collaboration with BeiGene to expand oncology presence in China

Amgen has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market.

Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology

Cycle Pharmaceuticals announced that it has signed an agreement with Catalent to develop innovative formulations targeting rare disease patients.

Pandion, Astellas sign $795m deal for pancreas-targeted immunomodulators

Pandion Therapeutics has signed a license and collaboration deal worth up to $795m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmune diseases of the pancreas.